Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Atr and parp kinase inhibitors: BayerRecent Research Landscape

Unchecked hyper-proliferative cell growth leads to treatment failure and tumor progression, which is mitigated by the targeted chemical inhibition of the ATR signaling pathway. This specific enzymatic blockade forces genomic instability in cancer cells to induce apoptosis.

What technical problems is Bayer addressing in Atr and parp kinase inhibitors?

Uncontrolled oncogenic cell proliferation

(19)evidences

Inadequate immune response against tumors limits therapeutic efficacy. Enhancing activation overcomes immunosuppressive barriers in the microenvironment.

Uncontrolled blood coagulation cascades

(18)evidences

Endogenous natriuretic peptides suffer from rapid proteolytic degradation and renal clearance. Extending systemic persistence enables sustained therapeutic signaling.

Insufficient ligand binding affinity

(18)evidences

Insufficient clinical response from single-agent treatments or non-selective targeting. Enhanced potency and selectivity overcome biological resistance and off-target limitations.

Therapeutic resistance to monotherapy

(16)evidences

Suboptimal drug exposure and off-target toxicity limit efficacy. Improving dosing schedules and targeting specificity enhances the window between therapeutic effect and adverse events.